The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has certified ARA Diagnostic Imaging's ARA Theranostics Center as a radiopharmaceutical therapy center of excellence.
The theranostics center, which opened in 2021, offers prostate specific membrane antigen-based therapy for prostate cancer and peptide receptor radionuclide therapy.